From Part D Redesign to MFPs: Developments and future strategies

With the recent implementation of the Inflation Reduction Act’s (IRA) Part D redesign changes and new Maximum Fair Price (MFP) dynamics beginning in 2026, the Medicare Advantage (MA) and Part D landscape for contracting and formulary management is rapidly evolving. The effects of 2025 Part D changes on beneficiary utilization, plan spending, and manufacturer liability are still emerging, while early insights into the 2026 plan landscape are revealing how Part D plans and manufacturers are navigating these shifts across different plan types, beneficiary populations, and therapeutic areas. 

In this webinar, Avalere Health Advisory experts explored emerging trends and implications for contracting, formulary strategies, and beneficiary access, including: 

• Observed impacts of Part D redesign on stakeholders in 2025, including differences for standalone Prescription Drug Plans (PDPs) vs. Medicare Advantage Prescription Drug Plans (MA-PDs), interactions with risk adjustment changes, and effects on beneficiary utilization 

• Early insights into 2026 plan offerings and formulary management changes 

• How MFP implementation is influencing plan formulary strategies for 2026 IPAY drugs and their competitors 

• Strategic considerations for CY 2027/2028 contracting, formulary positioning, and access approaches, as stakeholders incorporate lessons from Part D redesign and prepare for expanded MFP implementation within an evolving Part D environment 

 

 

Moderator:

• Kylie Stengel, Principal, Policy

Panelists:

• Mina Allo, Managing Director, Market Access
• Neil Lund, Senior Advisor, Policy
• Mark Newsom, Managing Director, Policy